Lana José Fábio, Purita Joseph, Everts Peter Albert, De Mendonça Neto Palmerindo Antonio Tavares, de Moraes Ferreira Jorge Daniel, Mosaner Tomas, Huber Stephany Cares, Azzini Gabriel Ohana Marques, da Fonseca Lucas Furtado, Jeyaraman Madhan, Dallo Ignacio, Santos Gabriel Silva
OrthoRegen Group, Max-Planck University, Indaiatuba 13343-060, Brazil.
PUR-FORM, Boca Raton, FL 33432, USA.
Gels. 2023 Jul 7;9(7):553. doi: 10.3390/gels9070553.
Platelet- and fibrin-rich orthobiologic products, such as autologous platelet concentrates, have been extensively studied and appreciated for their beneficial effects on multiple conditions. Platelet-rich plasma (PRP) and its derivatives, including platelet-rich fibrin (PRF), have demonstrated encouraging outcomes in clinical and laboratory settings, particularly in the treatment of musculoskeletal disorders such as osteoarthritis (OA). Although PRP and PRF have distinct characteristics, they share similar properties. The relative abundance of platelets, peripheral blood cells, and molecular components in these orthobiologic products stimulates numerous biological pathways. These include inflammatory modulation, augmented neovascularization, and the delivery of pro-anabolic stimuli that regulate cell recruitment, proliferation, and differentiation. Furthermore, the fibrinolytic system, which is sometimes overlooked, plays a crucial role in musculoskeletal regenerative medicine by regulating proteolytic activity and promoting the recruitment of inflammatory cells and mesenchymal stem cells (MSCs) in areas of tissue regeneration, such as bone, cartilage, and muscle. PRP acts as a potent signaling agent; however, it diffuses easily, while the fibrin from PRF offers a durable scaffolding effect that promotes cell activity. The combination of fibrin with hyaluronic acid (HA), another well-studied orthobiologic product, has been shown to improve its scaffolding properties, leading to more robust fibrin polymerization. This supports cell survival, attachment, migration, and proliferation. Therefore, the administration of the "power mix" containing HA and autologous PRP + PRF may prove to be a safe and cost-effective approach in regenerative medicine.
富含血小板和纤维蛋白的生物制品,如自体血小板浓缩物,已针对其对多种病症的有益作用进行了广泛研究并得到认可。富血小板血浆(PRP)及其衍生物,包括富血小板纤维蛋白(PRF),已在临床和实验室环境中显示出令人鼓舞的结果,尤其是在治疗骨关节炎(OA)等肌肉骨骼疾病方面。尽管PRP和PRF具有不同的特性,但它们具有相似的属性。这些生物制品中血小板、外周血细胞和分子成分的相对丰富刺激了众多生物学途径。这些途径包括炎症调节、增强的新血管形成以及提供促合成代谢刺激,从而调节细胞募集、增殖和分化。此外,有时被忽视的纤维蛋白溶解系统通过调节蛋白水解活性并促进炎症细胞和间充质干细胞(MSC)在组织再生区域(如骨骼、软骨和肌肉)的募集,在肌肉骨骼再生医学中发挥着关键作用。PRP作为一种有效的信号传导剂;然而,它容易扩散,而PRF中的纤维蛋白提供持久的支架作用,促进细胞活性。纤维蛋白与透明质酸(HA)(另一种经过充分研究的生物制品)的组合已被证明可改善其支架特性,导致更强大的纤维蛋白聚合。这支持细胞存活、附着、迁移和增殖。因此,在再生医学中,给予含有HA和自体PRP + PRF的“强力组合”可能被证明是一种安全且具有成本效益的方法。